Photo: NeuroStar TMS Therapy(R) Receives Prestigious Popular Science Award

Innovative device for the treatment of depression named one of 2009's 'Best of
What's New'

MALVERN, Pa., Nov. 12 /PRNewswire/ --

Quick Facts
-- Neuronetics' NeuroStar® Transcranial Magnetic Stimulation (TMS)
Therapy
has been selected by Popular Science as one of the "Best of What's
New"
in the health category for 2009, announced in November.
-- NeuroStar TMS Therapy is the first and only non-systemic (does not
circulate in the bloodstream) and non-invasive (does not involve
surgery) depression treatment cleared by the FDA.
-- NeuroStar is effective and safe in the treatment of depression; it
provides a new and unique option for the millions of depressed
patients
who have not benefited from prior antidepressant medications.*
-- Prior to the availability of NeuroStar TMS Therapy, many depressed
patients without improvement from antidepressants had only limited
options, including complex and often unproven regimens of multiple
drugs, or for the more severe cases, invasive procedures.

-- Unlike these alternatives, NeuroStar TMS Therapy does not cause
systemic side effects such as weight gain, sexual dysfunction,
nausea, dry mouth or sedation.

To view the Multimedia News Release, go to:
http://multivu.prnewswire.com/mnr/neuronetics/41162/

Spokespeople Comments

"We are very proud to have our NeuroStar TMS Therapy system honored as a
recipient of this year's Popular Science 'Best of What's New' Award. The
announcement is a great testament to the numerous researchers, engineers,
designers and clinicians who have been working tirelessly to bring this
innovative medical device to the millions of people in need of a new treatment
option for depression," said Neuronetics' President and CEO, Bruce Shook.

"For 22 years, Popular Science has honored the innovations that surprise and
amaze us - those that make a positive impact on our world today and challenge
our views of what's possible in the future," said Mark Jannot, Editor-in-Chief
of Popular Science. "The 'Best of What's New' Award is the magazine's top
honor and the 100 winners - chosen from among thousands of entrants -
represent the highest level of achievement in their fields."

NeuroStar TMS Therapy: Key Facts
-- NeuroStar TMS Therapy was cleared by the FDA in October 2008.
NeuroStar
TMS Therapy is specifically indicated for the treatment of Major
Depressive Disorder in adult patients who have failed to achieve
satisfactory improvement from one prior antidepressant medication at
or
above the minimal effective dose and duration in the current episode.
-- In an open-label clinical trial, which is most like real world
clinical
practice, approximately 1 in 2 patients experienced significant
improvement in symptoms, and 1 in 3 experienced complete symptom
resolution.

-- There were no systemic side effects observed with TMS Therapy, such as
weight gain and sexual dysfunction. The most common adverse events
related to treatment were scalp pain or discomfort at the treatment
area
during active treatments.

NeuroStar TMS Therapy: How it Works
-- Treatment with NeuroStar TMS Therapy activates nerve cells in an area
of
the brain that is linked to depression by delivering highly focused
MRI-strength magnetic field pulses.

-- The treatment is a 40-minute outpatient procedure that is performed
under supervision of a psychiatrist, does not require anesthesia or
sedation, and is administered daily for 4-6 weeks.

NeuroStar TMS Therapy may not be effective for all patients with depression
and is contraindicated in patients with metallic implants in or around the
head.

NeuroStar TMS Therapy: Availability

Treatment with NeuroStar TMS Therapy is available by prescription only from a
psychiatrist. It is available or will soon be available at more than 100
treatment centers in the U.S. For specific information on treatment locations
with NeuroStar TMS Therapy, please visit www.NeuroStarTMS.com or call the
Neuronetics Customer Service Center at (877) 600-7555.

Facts About Depression

Depression can affect anyone, regardless of race, age, gender or lifestyle.
-- 33 to 35 million Americans reported being diagnosed with depression
within their lifetime.
-- 13 to 14 million adults reported being diagnosed with depression
within
the past 12 months.
-- Women are affected almost twice as often as men.
-- The economic burden of depression in 2000 was estimated at $83.1
billion
in the U.S.
-- Researchers estimate that by the year 2020, depression will be the
second leading cause of disability worldwide.

-- Nearly 30 percent of patients with depression do not benefit from or
are
intolerant of antidepressant medication therapy.

About Neuronetics

Neuronetics, Inc. is a privately-held medical device company focused on
developing non-invasive therapies for psychiatric and neurological disorders
using MRI-strength magnetic field pulses. Based in Malvern, PA, Neuronetics is
the leader in the development of TMS Therapy, a non-invasive form of
neuromodulation. For more information, please visit www.neuronetics.com.

NeuroStar®, NeuroStar TMS Therapy®, and TMS Therapy® are registered trademarks
of Neuronetics, Inc.

*NeuroStar TMS Therapy® is indicated for the treatment of Major Depressive
Disorder in adult patients who have failed to achieve satisfactory improvement
from one prior antidepressant medication at or above the minimal effective
dose and duration in the current episode.

SOURCE Neuronetics, Inc.

Nancie Steinberg, Chamberlain Communications, +1-212-884-0667,
nsteinberg@chamberlainpr.com